P. Berghammer et al., ARTERIAL HEPATIC EMBOLIZATION OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA USING A CYANOACRYLATE LIPIODOL MIXTURE/, Cardiovascular and interventional radiology, 21(3), 1998, pp. 214-218
Purpose: A survival analysis in 16 patients with unresectable hepatoce
llular carcinoma (HCC) undergoing transcatheter arterial embolization
(TAE) using a combination of lipiodol and N-butyl-2-cyanoacrylate (5:1
) was performed in a retrospective study. Methods: A combination of li
piodol and N-butyl-2-cyanoacrylate (5:1) was used for TAE. All patient
s had disease compatible with Okuda stages I and II. Results: Twenty-f
our embolizations were done; five patients had more than one embolizat
ion. Median alpha-fetoprotein levels declined from 116 to 48.6 ng/ml.
A median of 0.3 ml cyanoacrylate was administered per patient. Median
survival was 8.5 months (range 2-49 months). After a median follow-up
of 4 years, 12 patients have died (75%). Okuda stage I and II patients
had a median survival time of 34.4 and 5.5 months respectively. Few s
ide effects (19%) were seen. Conclusion: We conclude that the TAE proc
edure used [lipiodol and N-butyl-2-cyanoacrylate (5:1)] is safe and pr
oduced only few side effects, thus constituting a valuable therapeutic
option for patients with Okuda stage I and II HCC.